A fibroinflammatory stromal reaction cooperates with oncogenic signaling to influence pancreatic ductal adenocarcinoma (PDAC) initiation, progression, and therapeutic outcome, yet the mechanistic underpinning of this crosstalk remains poorly understood. Here we show that stromal cues elicit an adaptive response in the cancer cell including the rapid mobilization of a transcriptional network implicated in accelerated growth, along with anabolic changes of an altered metabolome. The close overlap of stroma-induced changes in vitro with those previously shown to be regulated by oncogenic Kras in vivo suggests that oncogenic Kras signaling-a hallmark and key driver of PDAC-is contingent on stromal inputs. Mechanistically, stroma-activated cancer cells show widespread increases in histone acetylation at transcriptionally enhanced genes, implicating the PDAC epigenome as a presumptive point of convergence between these pathways and a potential therapeutic target. Notably, inhibition of the bromodomain and extraterminal (BET) family of epigenetic readers, and of Bromodomain-containing protein 2 (BRD2) in particular, blocks stroma-inducible transcriptional regulation in vitro and tumor progression in vivo. Our work suggests the existence of a molecular "AND-gate" such that tumor activation is the consequence of mutant Kras and stromal cues, providing insight into the role of the tumor microenvironment in the origin and treatment of Ras-driven tumors.
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pancreatic ductal adenocarcinoma | tumor microenvironment | cancer metabolism | BRD2 | histone acetylation T he tissue microenvironment plays important roles in directing development and differentiation but is also required for normal tissue homeostasis, working in part through secreted factors that control epithelial cell growth and survival (1) . Disruptions in this tissue homeostatic mechanism accompany solid tumor progression, enabling cancer cells to overcome the barriers to tumorigenesis imposed by normal tissue architecture (2) . In pancreatic ductal adenocarcinoma (PDAC), the dense fibroinflammatory stroma is largely attributed to soluble and extracellular matrix components secreted by cancer-associated fibroblasts [CAFs; derived predominantly from activated pancreatic stellate cells (PSCs)] (3).
The microenvironment surrounding PDAC undergoes dynamic alterations including aberrant immune responses and the accumulation of a fibroinflammatory stroma (4, 5) , alterations co-opted from the wound-healing response (6) . This cellular compartment not only cooperates with oncogenic alterations to drive pancreatic tumorigenesis (7, 8) but compromises the efficacies of cytotoxic and immune-targeted therapies (9) (10) (11) (12) . Stromal alterations during pancreatic tumorigenesis include activation of tissue-resident stellate cells: Although stellate cells contribute to tissue homeostasis and maintenance of the basement membrane under normal conditions (13) , these cells transdifferentiate into myofibroblast-like cells in the context of tissue damage or during pancreatic tumor progression (14) . PSC activation features robust induction of a transcriptional program that drives a fibroinflammatory response, including extracellular matrix components, cytokines, and growth factors (15) . Activated PSCs are a rich repository for secreted factors that may have diverse effects on neighboring epithelial cells, yet the nature of this interaction remains incompletely understood. Indeed, recent work suggests both tumor-supportive (16, 17) and tumor-suppressive or homeostatic (18) (19) (20) roles for the PDACassociated stroma, suggesting that an improved understanding of the molecular basis of tumor-stroma interactions may enable identification and targeting of tumor-supportive mechanisms.
Results
To explore the role of CAF-derived signals in gene regulation in the PDAC epithelial compartment, pancreatic cancer cells were Significance Stromal fibroblasts of the pancreatic tumor microenvironment (TME) have been shown to play both tumor-supportive and tumor-suppressive roles in enacting a dysregulated woundhealing response. This apparent complexity suggests that an improved understanding of the molecular basis of cell-cell interactions in the TME is required to identify and target stroma-derived, growth-permissive mechanisms. Here we show that stromal cues induce transcriptional and metabolic changes in pancreatic cancer cells implicated in anabolic metabolism, which overlap with those previously demonstrated downstream of oncogenic Kras. Stromal signals broadly induce histone acetylation in the pancreatic cancer epigenome, and we highlight inhibition of acetyl-lysine sensing by the bromodomain and extraterminal (BET) bromodomain family, Bromodomain-containing protein 2 (BRD2) in particular, as a potential therapeutic strategy.
grown in hyaluronic acid-based hydrogels in the presence (stromal) or absence (astromal) of collagens and soluble stromal cues (from patient-derived CAFs or in vitro activated PSCs, which secrete similar levels of cytokines, growth factors, ECM components, and remodeling factors) (15) . In response to stromal cues, PDAC cell lines grown in this 3D culture system increased the expression of the secreted factors CSF2 and CXCL1, without any apparent change in morphology or initial cell growth ( Fig. 1  A and B and Fig. S1A ). Furthermore, RNA-seq analyses showed broad effects of stromal inputs on transcription, with the expression of 332 and 128 genes up-and down-regulated, respectively, in MIAPaCa2 cells and 480 up-regulated and 406 down-regulated genes in p53 2.1.1 cells (>1.5-fold; Fig. 1C ). KEGG enrichment analyses of significantly up-regulated genes identified similar pathways activated in p53 2.1.1 and MIAPaCa2 cells, including cell cycle, DNA replication, and metabolic pathways ( Fig. 1D and Fig. S1B ). Indeed, a stroma-inducible signature, defined as the 86 genes up-regulated by stromal cues in both MIAPaCa2 and p53 2.1.1 cell lines, is enriched for genes in metabolic pathways as well as nucleoporins (Fig. 1E) , pathways shown to be up-regulated during pancreatic cancer progression in mice (21) . The induction of selected genes was validated by quantitative PCR (qPCR) (Fig.  1F and Fig. S1C ). Importantly, similar effects of stromal cues are evident in laser-microdissected human pancreatic cancer ( Fig.  1G ; low IL6 expression indicates little stromal contamination of tumor samples). Collectively, these results indicate that the stromal secretome is sufficient to regulate the expression of diverse gene classes in pancreatic cancer cells.
Interestingly, the gene sets induced by stromal cues in vitro overlap significantly with those activated by an inducible allele of Kras G12D in vivo (22) , suggesting that permissive signals from stroma drive oncogene-driven transcription in vivo ( Fig. 2A) . This finding is consistent with reports that a fibroinflammatory stromal reaction cooperates with oncogenic alterations in Kras to drive pancreatic cancer progression, whereas mutant Kras alone is insufficient to drive tumorigenesis (8) . Supporting this apparent functional convergence, qPCR analyses confirm that the stromal secretome up-regulates genes across multiple functional categories, including downstream Kras G12D targets involved in immune modulation (e.g., Csf2) (23, 24) and anabolic metabolism (e.g., Rrm2, Sc4mol) (Fig. 2B) . Consistent with changes in metabolic genes, stroma-activated PDAC cells consumed more glucose (∼40-90%; Fig. 2C and Fig. S2 A and B) and secreted more lactate (40-60%; Fig. 2D ), without significant effects on glutamine consumption (Fig. S2C) . Furthermore, intracellular metabolomics revealed that stromal cues dramatically alter cellular metabolism, increasing intermediates in glycolysis, the pentose phosphate pathway, downstream steps in nucleic acid synthesis, and the TCA cycle ( Fig. 2E and Fig. S2D ). Although PDAC cells grow to a similar extent in the presence or absence of stromal cues under nutrient-replete conditions ( Fig. S1A ), human pancreatic tumors are nutrient-poor and in particular feature low levels of glucose and glutamine (25) . Under nutrient-deprived conditions relevant to the microenvironment of human PDAC, stromal cues significantly increased the viability of PDAC cells, consistent with paracrine activation of an adaptive transcriptional survival program (Fig. 2F) . Together, these results suggest that the stromal reaction marshals genomic and metabolic responses in PDAC cells that enforce oncogenic signaling.
To understand how the stroma authorizes gene expression in PDAC cells, we explored acute changes in histone acetylation marks that differ between stroma-rich and stroma-poor regions of human PDAC (26), although we do not exclude effects of additional histone marks. Accordingly, PDAC cells exposed to soluble stromal cues showed increased levels of acetylation at both H3K9 (a marker of active promoters) and H3K27 (a marker of active enhancers; Fig. 3A ). Oncogenic Kras induces histone acetylation in vivo (27) , implicating epigenetic alterations as a putative point of convergence between oncogenic and microenvironmental signals. A time course revealed surprisingly rapid changes in histone acetylation, detectable within 1-3 h (Fig. 3B ), arguing against a requirement for de novo protein synthesis to induce these acetylation changes. To understand the transcriptional consequences of these epigenetic alterations, we localized sites of differential histone acetylation using targeted (ChIPqPCR) and global (ChIP-Seq) analyses in PDAC cells grown under astromal or stromal conditions. Notably, stromal cues dramatically increased H3K9 acetylation in promoter regions across the genome (Fig. 3 C and D) . The top 5% of differentially acetylated protein-coding genes are enriched for cancer pathways, including pancreatic cancer (Fig. 3E ), suggesting that stromal cues achieve their impact in part by coordinated chromatin-dependent remodeling of functionally related gene sets. Consistent with these genome-wide studies, site-specific ChIP-qPCR revealed increased acetylation at promoter and enhancer regions in the context of stromal signals (Fig. 3F ). These results demonstrate that microenvironmental cues rapidly regulate histone acetylation at a subset of promoters and enhancers in PDAC cells. Given the extent of the epigenetic changes, we postulated that effectors of this paracrine regulation may be susceptible to therapeutic inhibition. To explore this notion, we targeted the interaction between acetylated histone tails and chromatin readers. As acetylated histone marks are known targets of bromodomain and extraterminal (BET) bromodomain-containing proteins (28-31), we explored the impact of the BET bromodomain inhibitor JQ1 on stroma-inducible gene expression in vitro and on tumor growth in vivo. Interestingly, although treatment of pancreatic tumor cells with JQ1 reduced the expression of hundreds of genes under both astromal and stromal conditions, about 450-475 genes were uniquely down-regulated by JQ1 under stromal conditions (Fig. S3A) . Notably, in the PDAC cell lines examined, this subset of genes (Fig. 4 A and B and Fig. S3B ) significantly overlaps (35-60%) with those induced by stromal cues, suggesting inverse transcriptional regulation by microenvironmental signals and JQ1. By extension, viability in the context of stromal cues was significantly reduced by JQ1 treatment in multiple PDAC cell lines, albeit to varying degrees (Fig. S3C) . Antitumor activity of JQ1 in pancreatic cancer has been described previously by Mazur et al. (32) ; in this study, the authors suggest that the antitumor effects of BET inhibition are likely due to effects on MYC as well as negative regulation of inflammatory gene expression. In agreement with this work, we observed downregulation of Myc with JQ1 treatment in the p53 2. RNA-seq but not in the MIAPaCa2 line. However, a number of inflammatory genes were down-regulated by JQ1 in both cell lines, consistent with the findings of Mazur et al., including IFIT2, IFIT3, IRF5, CXCL5, and CXCL2 in MIAPaCa2 cells and Il34, C3, Cxcl1, Ccl2, and Cxcl5 in p53 2.1.1 cells. The expression of BET family members Bromodomain-containing proteins 2, 3, and 4 (BRD2, BRD3, and BRD4) (33, 34) in PDAC lines (Fig.  S3D ) raises the question as to which might be dominant in stroma-activated gene expression. Unexpectedly, BRD2 knockdown most closely phenocopied JQ1 treatment and down-regulated genes induced under stromal conditions (Fig. 4C ). This is confirmed by increased BRD2 binding to promoters of stromainducible genes, measured by ChIP assay (Fig. 4D) . These findings make an interesting contrast with the recent observation that stellate cell activation during the stromal response is principally mediated by BRD4 (35) , suggesting the potential for cellspecific functions of different BET bromodomain proteins in the tumor ecosystem.
To assess whether disruption of BET family activity could affect pancreatic tumor growth in vivo, we used orthotopic transplantation of luciferase-labeled PDAC cells into the pancreata of syngeneic hosts (Fig. S4A) . Impressively, JQ1 treatment significantly reduced pancreatic tumor growth and pancreas wet weight at the study endpoint (Fig. 4 E and F and Fig. S4B ), consistent with previous results (32, 36) . In addition, significant reductions in proliferation and immune cell infiltration were seen ( Fig. S4 C  and D) , consistent with the negative regulation of transcriptional programs promoting anabolic metabolism and inflammation. To assess the specific role of BRD2, we transduced luciferase-labeled p53 2.1.1 PDAC cells with a doxycycline-inducible shRNA targeting Brd2 (Fig. S5 A and B ) before orthotopic transplantation ( Fig. S5 C and D) . Notably, doxycycline treatment significantly reduced pancreatic tumor growth by over 50%, correlating with the reduced BRD2 protein levels in the tumors (Fig. S5 E-G) . When this study was performed alongside a doxycycline-inducible nontargeting control hairpin and an independent inducible shBrd2 clone, tumor growth in the control group was unaffected by doxycycline, whereas tumor growth in the inducible shBrd2 group was significantly reduced by docycycline (Fig. S5H) . To confirm these results in a different system, FC1245 PDAC cells derived from KPC mice were transduced with inducible shBrd2 or an inducible control hairpin as described above and used for orthotopic transplantation. Doxycycline significantly reduced tumor growth in the inducible shBrd2 line, whereas the control cell line was unaffected by doxycycline treatment (Fig. 4G ). Significant growth differences were noted between the shControl and shBrd2 cell in vivo in the absence of doxycycline, which may reflect leaky expression of shBrd2 in vivo in this system or may indicate a less aggressive clone. These results directly implicate the BET family of proteins as a viable therapeutic target in pancreatic cancer, in part due to effects on gene expression via transduction of the cancer epigenome.
Discussion
Despite the well-acknowledged role of the TME in modulating tumor growth and progression, an underlying molecular mechanism illuminating its effect is rudimentary at best. We show that a cell-free extract of secreted factors from cultured stromal cells is sufficient to dramatically alter survival of cultured PDAC cell lines under relevant conditions of nutrient challenge. This survival response is linked to a rapid change in transcriptional networks driving core metabolic pathways in the TCA cycle, anabolic metabolism and cell growth. The demonstration that the microenvironmental context broadly influences the epigenetic state of the tumor suggests that either side of this dynamic equationtumor or tumor microenvironment (TME)-can individually or possibly cooperatively serve as therapeutic targets. Interestingly, recent work has shown that tissue-specific microenvironmental signals can shape chromatin landscapes to support cellular function in distinct populations of resident macrophages (37, 38) . Together with our work, these studies raise the possibility that microenvironmental context broadly influences the epigenetic state of shControl +Dox: n = 8; shBrd2 -Dox: n = 8; shBrd2 +Dox: n = 8. P values determined by one-way ANOVA and Bonferroni post hoc test; ***P < 0.001; ****P < 0.0001; n.s., not significant. (H) Model depicting the complex interplay between stromal fibroblast-derived signals and pancreatic cancer cells in the TME.
tissue-resident cell types under physiological and pathological conditions. In the context of the wound-like TME, TME-induced transcriptional and metabolic changes overlap with those induced by oncogenic Kras, which presumably on its own cannot fully enable proliferation and viability in a nutrient-poor microenvironment. Although we have not identified a specific microenvironmentderived factor that regulates transcription and metabolism in a paracrine manner, our previous work identified numerous secreted factors that are transcriptionally up-regulated during stromal activation in pancreatic cancer and that may serve to regulate transcription and metabolism in the epithelial compartment (15) . These include factors that activate Ras-MAPK signaling via cell surface receptors to augment MYC activity, including connective tissue growth factor (39), hepatocyte growth factor (40) , and insulinlike growth factor binding proteins 2, 3, and 7 (which signal to EGFR indirectly via sphingosine-1-phosphate) (41) . Stromal PSCs also produce Il6, which can activate STAT3 in a paracrine manner to transcriptionally activate MYC (42) (43) (44) and induce associated metabolic and transcriptional changes. We propose that microenvironmental regulation of gene expression cooperates with cellautonomous pathways to fortify cancer cell viability by co-opting an otherwise normal, and usually transient, wound-healing response. Collectively, this work describes a connection between the stromal response and a driver oncogene (Fig. 4H ) and may offer new insights into the role of the microenvironment and the treatment of Ras-driven tumors. ; Pdx1-Cre mouse. Mouse PSCs were isolated from healthy pancreata of wild-type C57BL/6J mice aged 6-12 wk by density centrifugation, as previously described (15) . Human cancer-associated stromal myofibroblasts were grown out of surgically resected PDAC samples as described previously (33) and provided by J. A. Drebin and P. J. O'Dwyer, University of Pennsylvania, in accordance with the Institutional Review Boards of the Salk Institute and the University of Pennsylvania. The stromal population was confirmed to lack KRAS exon 2 mutations and was immortalized with SV40 large T antigen (pLenti-SV40-T, Applied Biological Materials Inc.) at a MOI of 2. This immortalized cell line was used for consistent generation of conditioned media for stromal cultures (described in 3D Astromal and Stromal Culture Generation below.). DMEM and RPMI 1640 were purchased from Life Technologies, and characterized FBS was purchased from HyClone. DMEM containing 10% (vol/vol) FBS was used to culture MIAPaCa2, Panc1, p53 2.1.1, and FC1245 cell lines as well as mouse PSCs and human PDACassociated stromal myofibroblasts. RPMI 1640 containing 10% (vol/vol) FBS was used to culture AsPC1 cells.
3D Astromal and Stromal Culture Generation. Astromal and stromal cultures were generated using the ESI BIO HyStem-C kit (BioTime, Inc.). Kit components were equilibrated to room temperature, and the suggested volume of degassed H 2 O was transferred to vials of Extralink (PEGDA), Gelin-S (thiolmodified denatured collagen), and Glycosil (thiol-modified hyaluronan) using a syringe and 25G needle to avoid opening the vials. Vials were vortexed every 5-10 min to aid reconstitution, and all reagents were in solution within 30 min. To generate astromal cultures, PDAC cells were resuspended in a solution of 1:1:1 degassed H 2 O:Glycosil:Extralink at a concentration of 5 × 10 5 cells per mL After careful mixing by pipetting, the suspension was added to a culture dish and placed in a 37°C incubator for 30 min to polymerize. To generate stromal cultures, PDAC cells were resuspended in a solution of 1:1:1 Gelin-S (collagens):Glycosil:Extralink at a concentration of 5 × 10 5 cells per mL, mixed by pipetting, and added to a culture dish. After 30 min in a 37°C incubator, both astromal and stromal cultures polymerized and the appropriate volume of DMEM containing 10% (vol/vol) FBS was layered over the hydrogels. The next day, media was removed, gels washed twice with sterile PBS, and DMEM containing 2% (vol/vol) FBS was added to astromal cultures or conditioned media containing 2% (vol/vol) FBS was added to stromal cultures. Cells appeared in single-cell suspension upon plating and expanded as spheroids over several days in 3D culture. Conditioned media for human PDAC lines was generated from immortalized stromal myofibroblasts grown out of surgically resected human PDAC. Stromal cells were grown to confluency and changed to fresh DMEM containing 2% (vol/vol) FBS. After 48 h, media was collected, spun down at 300 × g for 5 min to remove dead cells and debris, and added to stromal cultures. Conditioned media for murine PDAC lines was generated from activated mouse PSCs. PSCs were isolated from wild-type C57BL/6J mice 6-12 wk of age; yield from five mice was pooled into one T25 flask and cultured for 7 d in DMEM containing 10% (vol/vol) FBS to generate confluent activated PSCs or myofibroblast-like cells. On day 7, media was changed to fresh DMEM containing 2% (vol/vol) FBS, and after 48 h, media was collected, spun down at 300 × g for 5 min to remove dead cells and debris, and added to stromal cultures. For applications requiring recovery of a single-cell suspension (i.e., ChIP or cell counting for metabolic assays), hydrogels were constructed as described above but using PEGSSDA (sold separately by BioTime, Inc.) as a cross-linker for both astromal and stromal conditions. Volumetric ratios were as listed above, but the PEGSSDA reagent was reconstituted at a 2× concentration to ensure efficient polymerization of the hydrogels.
Gene Expression Analysis from 3D Cultures. For RNA isolation from 3D cultures, TRIzol (Life Technologies) was added to each well (the same volume as the hydrogel volume per well). TRIzol and hydrogel were resuspended by pipetting up and down through a cut pipet tip, transferred to 2.8-mm ceramic bead tubes, and homogenized at 3,000 rpm for 20 s in a PowerLyzer 24 (tubes and homogenizer; MO BIO Laboratories, Inc.). RNA isolation was then performed per the manufacturer's protocol. Reverse transcription was performed using the iScript cDNA Synthesis Kit per the manufacturer's protocol (Bio-Rad Laboratories, Inc.), and qPCR was carried out using SYBR Green master mix on a CFX384 Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.). Primer sequences are provided in Dataset S1.
RNA-Seq. RNA-Seq from astromal and stromal conditions was performed after 24 h of conditioned media addition or 48 h of growth in 3D culture. JQ1 treatments (500 nM, provided by J. Bradner, Dana-Farber/Harvard Cancer Center) were administered for the last 16 h of culture. Total RNA was isolated using TRIzol (Life Technologies) and the Rneasy mini kit with on-column Dnase digestion (QIAGEN). Library preparation, sequencing, and analysis procedures are described in SI Materials and Methods.
Metabolite Measurements. Glucose, lactate, and glutamine consumption were measured using a YSI 2950 analyzer. For this, PDAC cells were seeded in astromal and stromal conditions with a PEGSSDA cross-linker. After 48 h in 3D culture in DMEM or CM, hydrogels were washed three times with sterile PBS and switched to fresh DMEM containing 2% (vol/vol) FBS. After 24 h, spent media samples were collected and compared with fresh media in biological triplicate using the YSI analyzer. PEGSSDA-based hydrogels were dissociated using 40 mM N-acetyl-cysteine (NAC) for 60-120 min per the manufacturer's protocol, and cells were counted. Metabolite consumption was calculated by subtracting spent media measurements from fresh media measurements and normalizing to cell number.
Metabolomics. For steady-state intracellular metabolite profiling, PDAC cells were seeded in 3D cultures (5 × 10 5 cells per mL hydrogel, 1 mL hydrogel per well in six-well plates) on day 1, and changed to DMEM containing 2% (vol/vol) FBS (astromal) or CM containing 2% (vol/vol) FBS (stromal) on day 2. On day 3, cell media was replaced with fresh media 2 h before extraction. Media was aspirated, and cold (-80°C) methanol was added to each well while plates were on dry ice. After 30 min of incubation at -80°C, hydrogels and methanol were scraped and transferred to prechilled tubes, and samples were centrifuged at 3,000 × g for 10 min at 4°C. Supernatants were recovered, centrifugation repeated, and supernatants dried down in a refrigerated speedvac and stored at -80°C until analysis. Cells seeded in parallel were analyzed by CellTiter-Glo, and results were used for normalization. Metabolites were analyzed in biological triplicate by liquid chromatography-MS/MS using selected reaction monitoring (SRM) in a 5500 QTRAP hybrid triple quadrupole mass spectrometer (AB/SCIEX) coupled to a Prominence UFLC HPLC system (Shimadzu). Data analysis was performed in MetaboAnalyst 3.0.
Western Blot Analysis. Western blots were performed as previously described (15) . Antibody information and additional details can be found in SI Materials and Methods.
Chromatin Immunoprecipitation and ChIP-Seq. For ChIP and ChIP-Seq experiments under astromal and stromal conditions, 3D cultures were constructed using the PEGSSDA cross-linker to facilitate rapid dissociation. ChIP, deep sequencing, and analysis were performed as described previously (35) . For additional details, see SI Materials and Methods.
Orthotopic Transplant Studies. The p53 2.1.1 luciferase-expressing PDAC cell line was used for orthotopic transplantation into immune-competent FVB/n hosts, as previously described (45) . All mouse experiments were performed with the approval of the institutional animal care and use committee (IACUC) of the Salk Institute. For further details, see SI Materials and Methods.
